Organigram Global Inc. - Common Shares (OGI)

Organigram Global (NASDAQ:OGI) reported a weaker second quarter for fiscal 2026, with management attributing the decline to operational issues in key product categories, softer Canadian cannabis market growth and continued challenges with international flower specifications. Chief Executive Officer

Cannabis stocks TLRY, CRON, OGI, and SNDL log momentum gains even as Congress moves to re-criminalize some hemp-derived THC products.

Organigram Global Inc (NASDAQ: OGI) shares are trading sharply higher Monday afternoon, joining a rally across the cannabis sector.

Organigram's Q3 sales rose 72% to $51.14 million, driven by Motif acquisition and global demand, with margin gains and positive cash flow expected.

Benzinga's 2025 cannabis conference revealed realism, reform hopes, and a hemp showdown. Jesse Redmond, Todd Harrison & others weigh in.

Big tobacco companies have made small investments in the cannabis space. Industry experts share with Benzinga what could be next for partnerships and investments.

Tilray is building a new adult beverage category with hemp THC drinks, as alcohol declines and competition from Big Tobacco heats up.

Organigram CEO Beena Goldenberg to retire after leading company to #1 in Canada and launching U.S. and global expansion plans.

Germany became the world's top importer of medical cannabis, but political pressure could challenge telehealth-driven growth.

Cannabis jobs fall while sales rise, Mujica's death sparks global reflection, and the DEA returns to old scare tactics. This week's top cannabis news.

Organigram's Q2 sales surged 74% to $45.7 million, driven by Motif and global growth, with net income swinging to CA$42.5 million from a loss a year ago.